NCT00748410View on ClinicalTrials.gov

Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 22, 2009

Primary Completion Date

December 12, 2009

Study Completion Date

December 12, 2009

Conditions
Colitis, Ulcerative
Interventions
DRUG

SB-656933

7 days repeat dose

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY